Remicade (infliximab) - J&J
Humira (adalimumab) - AbbVie
Stelara (ustekinumab) - J&J
A Giant Intra-Abdominal Plasmablastic Neoplasm Favoring Lymphoma Mimicking an Exacerbation of Severe Fistulizing Crohn's Disease: A Case Report. (PubMed, Am J Case Rep) - Oct 10, 2026 - "CASE REPORT A 44-year-old woman with severe fistulizing Crohn's disease treated sequentially with adalimumab, infliximab, and ustekinumab developed progressive systemic deterioration despite partial intestinal stabilization. CONCLUSIONS Discordance between apparent intestinal control and systemic deterioration should prompt urgent tissue diagnosis. The findings favor PBL within the spectrum of plasmablastic neoplasms but neither establish drug-specific causation nor definitively exclude plasmablastic myeloma." 
Journal • B Cell Lymphoma • Cardiovascular • Crohn's disease • Epstein-Barr Virus Infections • Gastroenterology • Hematological Disorders • Hematological Malignancies • Hypertension • Immunology • Infectious Disease • Inflammatory Bowel Disease • Large B Cell Lymphoma • Lymphoma • Multiple Myeloma • Non-Hodgkin's Lymphoma • Oncology • Palliative care • Portal Hypertension • Thrombosis • ALK • CD20 • IRF4 • MME • MYC • PAX5 • PTPRC • SDC1
http://www.ncbi.nlm.nih.gov/pubmed/42850874
 
Kaja G?owacka; Marek Waluga
 
Oct 10, 2026
 
Prev Next